Article Type
Changed
Mon, 03/13/2023 - 17:49

Key clinical point: Rimegepant was effective for the acute treatment of migraine in patients who responded inadequately to 1 or ≥2 triptans and in current triptan users.

 

Major finding: Rimegepant was more effective than placebo at 2 hours postdose in providing freedom from pain and the most bothersome symptom (MBS) in patients with an inadequate response to 1 (both P < .001) and ≥2 (P  =  .013 and P < .001, respectively) triptans and in current triptan users (both P < .001). Among triptan-naive patients, rimegepant vs placebo significantly improved pain freedom (P  =  .007) but not MBS (P  =  .06).

 

Study details: This was a post hoc analysis of three phase 3 randomized controlled trials including 3507 patients with migraine who had (35.2%) or did not have (64.8%) inadequate response to triptans and who received rimegepant (n = 1749) or placebo (n = 1758).

 

Disclosures: This study was funded by Biohaven Pharmaceuticals, Inc. Six authors declared being employees of or holding stocks in Biohaven. Some authors declared ties with various sources.

 

Source: Lipton RB et al. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials. Cephalalgia. 2023;43(2):3331024221141686 (Feb 5). Doi: 10.1177/03331024221141686

Publications
Topics
Sections

Key clinical point: Rimegepant was effective for the acute treatment of migraine in patients who responded inadequately to 1 or ≥2 triptans and in current triptan users.

 

Major finding: Rimegepant was more effective than placebo at 2 hours postdose in providing freedom from pain and the most bothersome symptom (MBS) in patients with an inadequate response to 1 (both P < .001) and ≥2 (P  =  .013 and P < .001, respectively) triptans and in current triptan users (both P < .001). Among triptan-naive patients, rimegepant vs placebo significantly improved pain freedom (P  =  .007) but not MBS (P  =  .06).

 

Study details: This was a post hoc analysis of three phase 3 randomized controlled trials including 3507 patients with migraine who had (35.2%) or did not have (64.8%) inadequate response to triptans and who received rimegepant (n = 1749) or placebo (n = 1758).

 

Disclosures: This study was funded by Biohaven Pharmaceuticals, Inc. Six authors declared being employees of or holding stocks in Biohaven. Some authors declared ties with various sources.

 

Source: Lipton RB et al. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials. Cephalalgia. 2023;43(2):3331024221141686 (Feb 5). Doi: 10.1177/03331024221141686

Key clinical point: Rimegepant was effective for the acute treatment of migraine in patients who responded inadequately to 1 or ≥2 triptans and in current triptan users.

 

Major finding: Rimegepant was more effective than placebo at 2 hours postdose in providing freedom from pain and the most bothersome symptom (MBS) in patients with an inadequate response to 1 (both P < .001) and ≥2 (P  =  .013 and P < .001, respectively) triptans and in current triptan users (both P < .001). Among triptan-naive patients, rimegepant vs placebo significantly improved pain freedom (P  =  .007) but not MBS (P  =  .06).

 

Study details: This was a post hoc analysis of three phase 3 randomized controlled trials including 3507 patients with migraine who had (35.2%) or did not have (64.8%) inadequate response to triptans and who received rimegepant (n = 1749) or placebo (n = 1758).

 

Disclosures: This study was funded by Biohaven Pharmaceuticals, Inc. Six authors declared being employees of or holding stocks in Biohaven. Some authors declared ties with various sources.

 

Source: Lipton RB et al. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials. Cephalalgia. 2023;43(2):3331024221141686 (Feb 5). Doi: 10.1177/03331024221141686

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Migraine, March 2023
Gate On Date
Thu, 02/24/2022 - 16:45
Un-Gate On Date
Thu, 02/24/2022 - 16:45
Use ProPublica
CFC Schedule Remove Status
Thu, 02/24/2022 - 16:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article